AVEO Pharmaceuticals is a biopharmaceutical company. Co.'s product candidates include: tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor; Ficlatuzumab, a hepatocyte growth factor inhibitory antibody for the treatment of a potential treatment for squamous cell carcinoma of the head and neck, acute myeloid leukemia; AV-203, an anti-ErbB3 specific monoclonal antibody with high ErbB3 affinity; AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 an inhibitory antibody specific to Notch 3 a pathway in cell-to-cell communication. The AVEO stock yearly return is shown above.
The yearly return on the AVEO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2013 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AVEO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|